Skip to main content
. 2018 Jun 5;119(2):141–152. doi: 10.1038/s41416-018-0127-5

Table 1.

Selected studies with platinum salts in gBRCA1/2m breast cancer

Study Disease Phase Total (n) BRCAm (n) TNBC (n) BRCAm ER+ (n) Treatment Response in overall population Response in patients with wtBRCA1/2 Response in patients with gBRCA1/2m Response in patients with BRCA1m
Advanced and metastatic breast cancer
TNT45 Metastatic TNBC or BRCA1/2 mutation BC III 376 43 363 12 Carboplatin vs docetaxel ORR: 31% with carboplatin vs 36% with docetaxel NR 68% with carboplatin vs 33% with docetaxel NR
TBCRC00948 Metastatic TNBC II 86 11 86 0 Cisplatin or carboplatin ORR: 25.6% (22/86) ORR: 19.7% (13/66) ORR: 54.5% (6/11) NR
NCT0161172747 Metastatic BC with a BRCA1 mutation II 20 20a 14 5 Cisplatin NR NR NR ORR: 80% CR: 45%
Brocade 2 NCT0150660982 Locally recurrent or metastatic BC with a gBRCA1/2 mutation II 99 99 42 56 (ER+ and/or PgR+) Paclitaxel/carboplatin/placebo (PCP) 61% NR 61% NR
Early-stage disease
NCT0163022685 Stage I–III BC with a BRCA1 mutation II 107 107b 82 16 Cisplatin NR NR NR pCR: 61%
GeparSixto/GBG 66 NCT0142688087,88 Stage I–III TNBC or HER2+ BC II/III 588 50

315

291 BRCA known

0 Backbone regimen ± carboplatin

With vs without carboplatin:

TNBC pCR: 53% vs 37%

291 BRCA known status: 57% vs 41%

With vs without carboplatin:

TNBC pCR: 55% vs 36%

With vs without carboplatin:

TNBC pCR: 65% vs 67%

NR

BC breast cancer, CR complete response, ER+ oestrogen receptor-positive, gBRCA1/2 germline BRCA1/2, HER2+ human epidermal growth factor receptor 2-positive, NR not reported, ORR overall response rate, pCR pathologic complete response, PgR+ progesterone receptor-positive, TNBC triple-negative breast cancer, wtBRCA1/2 wild-type BRCA1/2

aAll were HER2-negative, 15 were ER-negative, 17 were PgR-negative, and 14 were TNBC

b100 were HER2-negative (5 HER2 status unknown), 86 were ER-negative (5 ER status unknown), 91 were PgR-negative (6 PgR status unknown), and 82 were TNBC